Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

Video

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Soft tissue sarcomas are rare and ​relatively heterogeneous malignancies, Pautier explains. ​Some subtypes, such as leiomyosarcoma, are associated with poor prognosis​ and therefore, have limited studies dedicated to ​them.

The LMS-02 trial evaluated the safety and efficacy of doxorubicin in combination with trabectedin in patients with metastatic ​or ​advanced uterine and soft tissue leiomyosarcoma.

To date, the ​first-line standard of care for this patient population is doxorubicin alone, Pautier concludes. 

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD